Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy after chemo may keep aggressive lymphoma at bay

NCT ID NCT03463057

Ongoing Disease control Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether the immunotherapy drug atezolizumab can help prevent relapse in people with high-risk diffuse large B-cell lymphoma (DLBCL) who have already achieved remission with standard chemotherapy (R-CHOP). About 109 adults aged 18–75 are receiving 18 cycles of atezolizumab followed by 12 months of observation. The main goal is to see if this approach improves disease-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atezolizumab (Tecentriq)
What this could lead to
If it works, this could offer a way to keep high-risk DLBCL in remission longer after initial chemotherapy.
What could go wrong
This is a mid-stage trial with only 109 participants, so results may not apply to everyone. Atezolizumab can cause immune-related side effects, and it's unclear if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL NHL

Contacts and locations

Locations

  • BE-Antwerpen Edegem-UZA

    Antwerp, Belgium

  • BE-Antwerpen-ZNASTUIVENBERG

    Antwerp, Belgium

  • BE-Brugge-AZBRUGGE

    Bruges, Belgium

  • BE-Leuven-UZLEUVEN

    Leuven, Belgium

  • BE-Roeselare-AZDELTA

    Roeselare, Belgium

  • NL-Amersfoort-MEANDERMC

    Amersfoort, Netherlands

  • NL-Amsterdam-OLVG

    Amsterdam, Netherlands

  • NL-Amsterdam-VUMC

    Amsterdam, Netherlands

  • NL-Apeldoorn-GELREAPELDOORN

    Apeldoorn, Netherlands

  • NL-Breda-AMPHIA

    Breda, Netherlands

  • NL-Delft-RDGG

    Delft, Netherlands

  • NL-Den Bosch-JBZ

    's-Hertogenbosch, Netherlands

  • NL-Den Haag-HAGA

    The Hague, Netherlands

  • NL-Dordrecht-ASZ

    Dordrecht, Netherlands

  • NL-Ede-ZGV

    Ede, Netherlands

  • NL-Eindhoven-CATHARINA

    Eindhoven, Netherlands

  • NL-Eindhoven-MAXIMAMC

    Eindhoven, Netherlands

  • NL-Enschede-MST

    Enschede, Netherlands

  • NL-Groningen-UMCG

    Groningen, Netherlands

  • NL-Hilversum-TERGOOI

    Hilversum, Netherlands

  • NL-Hoofddorp-SPAARNEGASTHUIS

    Hoofddorp, Netherlands

  • NL-Leeuwarden-MCL

    Leeuwarden, Netherlands

  • NL-Leiden-LUMC

    Leiden, Netherlands

  • NL-Maastricht-MUMC

    Maastricht, Netherlands

  • NL-Nieuwegein-ANTONIUS

    Nieuwegein, Netherlands

  • NL-Nijmegen-CWZ

    Nijmegen, Netherlands

  • NL-Rotterdam-ERASMUSMC

    Rotterdam, Netherlands

  • NL-Rotterdam-MAASSTADZIEKENHUIS

    Rotterdam, Netherlands

  • NL-Sittard-Geleen-ZUYDERLAND

    Sittard, Netherlands

  • NL-Tilburg-ETZ

    Tilburg, Netherlands

  • NL-Utrecht-UMCUTRECHT

    Utrecht, Netherlands

  • NL-Zwolle-ISALA

    Zwolle, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.